Voya Investment Management LLC Boosts Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)

Voya Investment Management LLC grew its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 6.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 76,789 shares of the company’s stock after purchasing an additional 4,943 shares during the period. Voya Investment Management LLC’s holdings in 10x Genomics were worth $1,103,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in TXG. Signaturefd LLC increased its stake in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after buying an additional 1,452 shares during the period. Blue Trust Inc. raised its stake in shares of 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after acquiring an additional 1,299 shares in the last quarter. Sound Income Strategies LLC boosted its holdings in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in 10x Genomics in the fourth quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. increased its holdings in 10x Genomics by 817.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock worth $70,000 after purchasing an additional 4,324 shares during the period. 84.68% of the stock is currently owned by institutional investors.

Insider Transactions at 10x Genomics

In related news, Director Alan Mateo purchased 40,000 shares of 10x Genomics stock in a transaction that occurred on Friday, February 21st. The stock was bought at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the transaction, the director now owns 61,691 shares in the company, valued at $687,237.74. The trade was a 184.41 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Serge Saxonov sold 5,092 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the sale, the chief executive officer now owns 879,482 shares in the company, valued at approximately $9,735,865.74. This represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 10.03% of the company’s stock.

10x Genomics Stock Performance

10x Genomics stock opened at $8.61 on Tuesday. The business’s 50-day simple moving average is $9.10 and its two-hundred day simple moving average is $12.73. The company has a market cap of $1.05 billion, a PE ratio of -5.66 and a beta of 1.94. 10x Genomics, Inc. has a fifty-two week low of $6.78 and a fifty-two week high of $28.25.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TXG. Leerink Partnrs downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. UBS Group dropped their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Leerink Partners lowered shares of 10x Genomics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $25.00 to $12.00 in a report on Thursday, February 13th. Citigroup dropped their price objective on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Finally, Barclays reduced their price objective on shares of 10x Genomics from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $18.85.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.